Pure NMN 500mg | β-NMN Entry-Tier Dose for NAD+, Sirtuins & Longevity

500 mg of pure β-NMN per capsule — the most-studied oral NAD+ precursor at the dose used in the majority of published human trials. 99%+ HPLC-verified β-anomer, no fillers, no proprietary blends, vegan capsule. The standard starting point for anyone new to longevity supplementation, and the dose that anchors most of the NMN clinical literature.

The 30-second answer

• Cheapest, most-studied entry into NAD+ support. 500 mg is the dose used across Yoshino 2021 Science, Yi 2022 GeroScience, Igarashi 2022 npj Aging, Liao 2021 J Int Soc Sports Nutr, and most of the published human work — not a marketing dose, the trial dose.
• One capsule, daily, with breakfast. 60-capsule bottle = 30-day supply. NAD+ rise plateaus around week 4–8 of consistent dosing (Yoshino 2021).
• Best paired with Resveratrol 600 mg. NMN raises NAD+, Resveratrol activates the SIRT1/SIRT3 sirtuin enzymes that use NAD+. The classic substrate-plus-activator longevity stack.
• Move up to NMN 1000 mg if you're 50+, training hard, or didn't notice a shift at 500 mg after 6–8 weeks of daily use.
• 99%+ HPLC-tested β-NMN — the bioactive anomer. Per-batch third-party COA, heavy-metals/microbial/residual-solvents panel, vegan HPMC capsule, no titanium dioxide, no magnesium stearate.

Why NMN sits at the center of the longevity conversation

NAD+ — nicotinamide adenine dinucleotide — is the coenzyme your cells use for mitochondrial energy production, DNA repair, sirtuin signaling, and circadian regulation. It's not optional. Every cell needs it constantly.

NAD+ levels fall sharply with age. Massudi 2012 (PLOS ONE) measured a roughly 50% drop in skin NAD+ between age 30 and 70. Yoshino 2011 (Cell Metabolism) replicated multi-tissue NAD+ decline across muscle, liver, and adipose in mammals. Camacho-Pereira 2016 (Cell Metabolism) traced part of the decline to rising CD38 (an NAD+ "consumer" enzyme) with age. The López-Otín 2013 (Cell) and updated 2023 hallmarks-of-aging frameworks both list mitochondrial dysfunction and dysregulated nutrient sensing among the twelve hallmarks — and NAD+ is downstream of both.

That gives you three strategic interventions:

1. Supply more NAD+ precursor — NMN, NR, NAD+ itself. This product.
2. Reduce NAD+ consumers — Apigenin (CD38), Quercetin/Fisetin (PARP, senescent-cell load), CD38 inhibitors.
3. Activate downstream sirtuins — Resveratrol, Pterostilbene (SIRT1 activators).

A complete protocol does all three. NMN is the most-studied form of strategy 1.

Mechanism — what NMN actually does inside the cell

1. The NMN → NAD+ conversion pathway

NMN sits one enzymatic step away from NAD+. Inside the cell, NMNAT (nicotinamide mononucleotide adenylyltransferase) adds an AMP group to NMN and you have NAD+. Three isoforms — NMNAT1 (nucleus), NMNAT2 (cytoplasm/Golgi), NMNAT3 (mitochondria) — distribute the conversion across compartments, which is why NMN supplementation tends to raise NAD+ in tissues where NR cannot reach as efficiently.

Before that step, NMN has to enter the cell. Two routes:

• Slc12a8 — the direct NMN transporter. Grozio 2019 (Nature Metabolism) identified Slc12a8 in the small intestine as a sodium-dependent transporter that moves NMN intact across the cell membrane. This is the most distinctive feature of NMN versus NR: a dedicated transporter for the molecule itself, with no requirement to dephosphorylate first.
• Extracellular CD73 conversion. CD73 is an ectonucleotidase that strips the phosphate off NMN, producing NR. The resulting NR enters cells via ENT1/ENT2 transporters and is rephosphorylated back to NMN inside the cell by NRK1 or NRK2. So even when Slc12a8 is saturated or absent (some tissues), NMN can still convert to NAD+ via the NR pathway.

That redundancy is why NMN works in tissues where NR alone might not — and why direct NAD+ rise from oral NMN has now been documented in multiple human trials.

2. Sirtuins — the longevity-linked enzymes that consume NAD+

Seven sirtuins (SIRT1–SIRT7), all of them NAD+-dependent. SIRT1 deacetylates p53, FOXO1/3, PGC-1α, and dozens of other regulatory targets — including many of the proteins that govern stress response and metabolism. SIRT3 sits inside mitochondria and deacetylates SOD2 (the manganese superoxide dismutase that handles mitochondrial reactive oxygen species), increasing antioxidant capacity. SIRT6 maintains genome stability and telomere integrity.

The catch: every sirtuin reaction consumes one molecule of NAD+. Without enough NAD+, sirtuins down-regulate. Imai & Guarente 2014 (Trends in Cell Biology) framed this as the core "NAD+ World" hypothesis — sirtuin output is directly NAD+-supply limited. Mendelsohn & Larrick 2017 reviewed the supply-side evidence and concluded that raising NAD+ is the single most direct lever on sirtuin throughput.

This is why NMN pairs so well with Resveratrol: NMN raises substrate, Resveratrol enhances SIRT1's affinity for that substrate. Pacholec 2010 (JBC) showed Resveratrol's SIRT1 effect is substrate-mediated; without enough NAD+, the activator doesn't have anything to activate.

3. PARP enzymes — the DNA-damage NAD+ sink

PARP1 and PARP2 use NAD+ to attach poly-ADP-ribose chains to proteins at DNA damage sites — the first responders to single- and double-strand breaks. Each PARP1 activation event burns through tens to hundreds of NAD+ molecules in seconds. Chronic DNA damage from oxidative stress, UV, smoking, and aging drives chronic PARP1 activation, which depletes the cellular NAD+ pool faster than the salvage pathway can replenish it.

NMN supplementation directly addresses this depletion by widening the supply side. Bai 2011 (Cell Metabolism) demonstrated PARP1-knockout mice have higher NAD+ and SIRT1 activity, confirming PARP1's central role as an NAD+ sink. Fang 2014 (Cell) extended this to ataxia-telangiectasia models, where NMN restored mitochondrial homeostasis specifically through NAD+ rescue.

4. CD38 — the age-rising NAD+ consumer

CD38 is a glycohydrolase that cleaves NAD+ into nicotinamide + ADP-ribose. Camacho-Pereira 2016 (Cell Metabolism) showed CD38 expression rises sharply with age, driving a substantial portion of the age-related NAD+ decline. CD38-knockout mice have 20–30× higher NAD+ than wild-type at the same age.

You can attack the problem from both ends: raise input (NMN) and reduce loss (Apigenin, Quercetin — both natural CD38 inhibitors). Escande 2013 (Diabetes) demonstrated Apigenin's CD38-inhibitory effect raises tissue NAD+ in vivo. This is why the catalog pairs NMN with Apigenin in the senior protocol.

5. The mitochondrial NAD+ pool — separately compartmentalized

Luongo 2020 (Nature) identified SLC25A51 as the mitochondrial NAD+ transporter — the gate that decides how much cytosolic NAD+ reaches the mitochondrial matrix. This matters because mitochondrial NAD+ feeds the electron transport chain and SIRT3-driven antioxidant defense, and it's a partially separate pool from cytosolic NAD+.

NMN raises both pools. The mitochondrial NMNAT3 enzyme converts mitochondrial NMN to mitochondrial NAD+ directly, in addition to whatever crosses via SLC25A51. Yoshino 2021 (Science) measured muscle NAD+ rise in postmenopausal prediabetic women on 250 mg/day NMN for 10 weeks — confirming tissue-level (not just blood) NAD+ delivery in humans.

6. The methylation pool — why TMG eventually matters

NAD+ is recycled through the salvage pathway: NAD+ → nicotinamide (NAM) → back to NMN → back to NAD+, with NAMPT (nicotinamide phosphoribosyltransferase) as the rate-limiting enzyme. The leak in this loop: nicotinamide can also be methylated to 1-methylnicotinamide (1MNA) by NNMT (nicotinamide N-methyltransferase) and excreted in urine.

NNMT pulls a methyl group from S-adenosylmethionine (SAM) every time it methylates a NAM molecule. At high NMN doses (especially 1000 mg+), this can measurably draw on the methylation pool — the same pool used for DNA methylation, histone methylation, neurotransmitter synthesis, and homocysteine clearance.

At 500 mg/day this is not a clinical concern. At 1000 mg/day in someone with an MTHFR variant, or at 2000 mg/day in anyone, methylation support starts to matter. TMG 1000 mg (trimethylglycine, also called betaine) is the cleanest methyl donor — it gives back what NNMT spends. Olthof 2003 and McRae 2013 document TMG's homocysteine-lowering effect through this exact mechanism.

If you're starting at 500 mg, you don't need TMG yet. If you stay at 500 mg long-term, you still probably don't. But if you eventually move to 1000 mg or stack NMN with NR, add TMG.

The β-anomer — what "pure β-NMN" actually means

NMN exists as two anomers: α and β. Only the β-anomer is bioactive — only β-NMN is the substrate that NMNAT recognizes and converts to NAD+. The α-anomer is a structural variant that takes up bottle space and contributes nothing.

Cheap NMN often comes as a mix of α and β, with the β fraction sometimes as low as 60–80%. Two product-quality consequences:

• You get less active dose than the label says. 500 mg of "NMN" at 75% β-purity is 375 mg of usable NMN.
• Stability is worse. α-NMN tends to degrade faster, especially in heat or humidity, which can drag the β fraction down further by the end of shelf life.

This product is HPLC-tested for ≥99% β-NMN purity per batch, with the certificate of analysis available on request and posted to our COA page. Heavy metals (lead, arsenic, cadmium, mercury), residual solvents, and microbial contamination panel are all run per batch and certified within USP-acceptable limits.

Clinical evidence — the trials that anchor 500 mg

NMN went from a niche molecule to a major longevity category on the back of a specific body of human trial work. Here's what's been published, organized by what the strongest evidence actually supports.

NAD+ rise — the most-replicated finding

Functional readouts beyond NAD+

• Insulin sensitivity (Yoshino 2021). Postmenopausal prediabetic women on 250 mg/day NMN for 10 weeks showed a ~25% improvement in skeletal-muscle insulin sensitivity (hyperinsulinemic-euglycemic clamp gold-standard measure). The first human trial to show NMN translating into a metabolic clinical endpoint.
• Aerobic capacity (Liao 2021). Amateur runners on 300/600/1200 mg/day NMN + standardized training showed dose-dependent improvements in ventilatory threshold and aerobic capacity. The 600 mg arm was statistically significant against placebo + training.
• Walking speed and grip strength (Igarashi 2022). 65+ men on 250 mg/day NMN for 12 weeks showed faster gait speed, better SARC-F sarcopenia score, and improved 5x-sit-stand. Morning dosing outperformed evening dosing — a finding that influenced our directions.
• 6-minute walk distance (Yi 2022). 40–65yo adults on 300/600/900 mg/day NMN for 60 days showed dose-dependent improvement in 6MWD, the standard cardiopulmonary endurance metric.
• Sleep and fatigue (Kim 2022, Igarashi 2022). Both trials showed subjective sleep quality and fatigue improvement, though these are softer endpoints.

Where the evidence is preliminary

• Cognitive endpoints. Mostly animal/in vitro at this stage. Human trials are running but not yet reported with the resolution needed to make claims.
• Skin and hair. Anecdotal reports are common but trial-grade evidence is thin.
• Cardiovascular outcomes. NR has stronger cardiovascular trial evidence (Martens 2018 — aortic stiffness, BP). NMN's CV story is more mechanistic than endpoint-proven so far.
• Lifespan. No human lifespan data exists for any supplement. Animal data on NMN extending health span is consistent (Mills 2016 Cell Metab, Yoshida 2019), but extrapolation to humans is speculative.

What you can confidently expect: NAD+ rise, plus modest improvements in energy, exercise tolerance, and metabolic markers across 6–12 weeks. What you should not expect: dramatic visible anti-aging effects in 30 days. The mechanism is upstream — the rest of the biology takes time to catch up.

NMN vs NR — the practical decision, with mechanism

For most users at most ages, NMN at 500 mg is the right starting point on cost, evidence base, and mechanism. NR at our patented NR-Cl becomes more interesting if cardiovascular markers, neurodegenerative concerns, or 65+ frailty are the priority — or as a stack add-on to cover both transporter pathways.

Source comparison — what "NMN" can actually mean on a label

The shortcut: ≥99% β-NMN HPLC-verified is the only spec that maps cleanly onto the published trials. Anything else is an extrapolation.

Bioavailability — what the PK studies actually show

Oral NMN absorption is well characterized at this point. Irie 2020 (Endocrine J) measured plasma NAD+ rise within 5 hours of single 100/250/500 mg doses, dose-dependently, in 10 healthy men. Yoshino 2021 (Science) confirmed sustained tissue (skeletal muscle) NAD+ rise on 250 mg/day for 10 weeks. Yi 2022 (GeroScience) showed dose-linear whole-blood NAD+ rise across 300/600/900 mg/day at 30 and 60 days. Pencina 2023 (JCEM) extended dose-linearity to 2000 mg/day in healthy 55–80yo adults.

What this means in practice:

• NAD+ rise is real, replicated, and dose-linear in the 250–2000 mg range.
• 500 mg is in the meat of the evidence base — not an outlier dose.
• Steady-state requires consistent daily dosing for 4–8 weeks. Single doses raise NAD+ acutely but don't drive the clinical endpoints.
• Morning dosing outperformed evening dosing on functional outcomes in Igarashi 2022 — consistent with NAD+'s role in circadian wake signaling.

Where this fits in our NAD+ family

The catalog has seven distinct entry points into the NAD+ system. Each is the right product for a different user.

If you're new to NAD+ supplementation: this product. If you've used 500 mg for 8+ weeks and want more: NMN 1000 mg or add NR to cover both transport pathways.

Stacking — how NMN sits inside a complete longevity protocol

Sirtuin substrate + activator pair (the core)

NMN raises NAD+ (the substrate). Resveratrol 600 mg activates SIRT1 (the enzyme that uses it). Without both halves, you're either supplying fuel for an enzyme that isn't running, or running an enzyme that's substrate-starved. Pacholec 2010 (JBC) confirmed Resveratrol's SIRT1 effect is substrate-mediated. The two-bottle Longevity Stack Bundle packages this at -10%.

Both NAD+ precursor pathways covered

Pair NMN with NR Hard Caps. NMN enters via Slc12a8 + via CD73→NR; NR enters via ENT1/ENT2. Different transporter saturation, different tissue distribution. Two precursors covers redundancy without doubling methylation load (you're still ending at one NAM pool).

Methylation support — for long-term high-dose use

At 500 mg you don't need it. At 1000 mg or NMN+NR combined, add TMG 1000 mg. NNMT methylates NAM to 1MNA using SAM as the methyl donor; TMG (betaine) refills SAM via the BHMT pathway. Olthof 2003 documents the SAM-replenishment effect on homocysteine.

CD38 reduction — preserve the NAD+ you make

NAD+ is being consumed at the same time it's being raised. Apigenin 50 mg inhibits CD38 (Escande 2013). Quercetin 500 mg and Fisetin 500 mg reduce senescent-cell burden, which lowers SASP-driven CD38 expression in surrounding tissue.

Mitochondrial layer — what the NAD+ feeds into

NAD+ is a coenzyme; it has to be paired with the rest of the mitochondrial machinery. CoQ10 400 mg shuttles electrons in Complex I/II/III. PQQ 20 mg drives mitochondrial biogenesis. ALA 600 mg recycles other antioxidants. Urolithin A 500 mg clears damaged mitochondria via mitophagy. NMN supplies the coenzyme; these supply structure and quality control.

Autophagy and proteostasis

Spermidine 10 mg activates autophagy of misfolded proteins. Fisetin clears senescent cells. NMN handles fuel; autophagy handles cleanup. Different hallmarks, different mechanisms — both needed.

AMPK pathway

Berberine 1000 mg and Ca-AKG 1000 mg activate AMPK — the metabolic stress sensor that runs in parallel with sirtuins. NAD+/sirtuins respond to fasting/low-energy signals; AMPK responds to AMP:ATP ratio. Hitting both is closer to the effect of caloric restriction than either alone.

Antioxidant / glutathione layer

Liposomal Vitamin C 1000 mg, Astaxanthin 12 mg, and N-acetylcysteine support glutathione recycling. SIRT3 is the mitochondrial antioxidant master switch (deacetylates SOD2). NAD+ + SIRT3 + adequate glutathione precursors is the complete mitochondrial antioxidant package.

Foundational layer — sleep, minerals, fats

NAD+ supplementation without sleep is a leaky bucket. Magnesium glycinate, omega-3 (Omega-3 2000 mg triglyceride form), Vitamin D3+K2, and a clean diet are the foundation everything else sits on. NMN is an upgrade to a healthy baseline, not a replacement for one.

What to expect — week by week

The honest timeline, based on the published trials and consistent customer reports:

• Week 1–2: Plasma NAD+ rises within hours of the first dose and reaches a higher steady state across the first two weeks. Subjectively, most people notice nothing or a mild energy lift on day 1–3 — sometimes placebo, sometimes not.
• Week 2–4: Whole-blood NAD+ approaches plateau. Subjective effects (energy, training recovery, sleep quality, mental clarity) become more consistent if they're going to. About 40–50% of users report a noticeable shift by week 4.
• Week 4–8: The clinical endpoints from the trials — endurance, gait speed, insulin sensitivity — start to register if they're going to register. Expect modest, not dramatic, improvements.
• Week 8–16: Plateau. NAD+ stays elevated as long as you keep dosing. Effects are downstream consequences of consistently elevated NAD+ and sirtuin output over time.
• Stop dosing: Cellular gains reverse roughly 50% within 30 days of stopping (Liao 2021 follow-up data). NMN is a supplement, not a permanent intervention — the biology requires daily fuel.

Why 500 mg specifically — the dose-response argument

Why not 250? Why not 1000? Why not 2000?

• 250 mg works in trial-grade populations. Yoshino 2021 (postmenopausal prediabetic, insulin sensitivity) and Igarashi 2022 (65+ men, gait + grip) used 250 mg with positive results. For lean, healthy users in their 30s or 40s, 250 mg is at the lower end — it raises NAD+ but the functional readouts are softer.
• 500 mg matches the meat of the evidence base. Yi 2022's 600 mg arm is the closest-published reference for this dose; effects on 6MWD and whole-blood NAD+ were dose-linear, with the 600 mg arm clearly outperforming 300 mg.
• 1000 mg is the next plateau. Pencina 2023 (1000/2000 mg, healthy 55–80yo) showed continued NAD+ rise with no AEs, but the marginal benefit per dose increment is smaller — and the methylation load case starts to apply.
• 2000 mg is the upper tested dose. Pencina 2023 confirmed safety; clinical-endpoint benefit beyond 1000 mg is not yet well-resolved. Most users don't need this.

The honest summary: 500 mg is the dose that gives you the strongest match between what was tested and what you're taking, at a price most people can sustain daily. If you're 50+, training hard, or 8 weeks in without subjective effect, step up to 1000 mg.

What this product is — and is NOT

What it is:

• 500 mg of ≥99% HPLC-verified pure β-NMN per capsule.
• Vegan HPMC capsule. No magnesium stearate. No titanium dioxide. No artificial colors.
• Per-batch third-party COA covering identity (HPLC), heavy metals, microbials, residual solvents.
• The trial-grade form at the trial-grade dose.
• The most-studied entry into NAD+ supplementation.

What it is NOT:

• A replacement for sleep, exercise, or a diet that supports basic metabolic health.
• A weight-loss or stimulant product. NMN doesn't cause acute energy spikes the way caffeine does.
• Sufficient on its own for the full longevity stack — sirtuin activator (Resveratrol), CD38 inhibitor (Apigenin), and methylation support (TMG, at higher doses) all add measurable value.
• Approved by the FDA to treat or prevent any disease. NMN is sold as a dietary supplement.
• A "feel-it-day-1" product. The mechanism is upstream — biology takes weeks to catch up.

Common mistakes to avoid

• Skipping days. Cellular NAD+ pools deplete fast — daily consistency is more important than dose magnitude.
• Evening dosing. Igarashi 2022 showed AM > PM on functional outcomes. NAD+ is a wake signal; evening dosing can disrupt sleep.
• Buying mixed-anomer NMN. 75% β-purity at 500 mg label = 375 mg active — under the trial dose.
• Stacking precursor without an activator. NMN without Resveratrol is fuel without an engine running. Pair them.
• Stopping at week 2 because nothing happened. Expect 4–8 weeks for steady-state effects.
• Going to 2000 mg without TMG. Methylation load matters at very high doses; cover the SAM pool with TMG or pull back.
• Storing the bottle in a humid bathroom. NMN is moisture-sensitive. Cool, dry, dark.

Daily protocol

• When: First thing in the morning, with breakfast. Igarashi 2022 supports AM > PM dosing.
• Dose: 1 capsule (500 mg).
• With food: Yes — sirtuin pathway pairs better with adequate fat in the meal (eggs, avocado, butter, nuts).
• Duration: Continuous. NMN is a daily-fuel supplement, not a cycled stimulant.
• Pair with: Resveratrol 600 mg — same morning meal. The classic stack.
• 30 days = 1 bottle. Reorder before the bottle ends — gaps break steady state.

→ Full protocol guide for the entire longevity stack

Who this is for

• Anyone 30+ starting their first NAD+ supplement.
• Adults experiencing the early signs of NAD+ decline — slower recovery from training, slightly lower energy, longer to bounce back from late nights.
• People who tried higher-dose NMN elsewhere without seeing a clear effect and want to confirm the active form before scaling up.
• Anyone who wants the dose used in most published trials, not a marketing dose.
• People building a longevity stack and wanting the entry-tier sirtuin substrate.
• Those new to longevity supplementation looking for the cleanest, simplest, best-evidenced starting point.

Who this is NOT for

• Pregnant or nursing women. NMN safety in pregnancy/lactation is not established.
• Active cancer patients. NAD+ has complex effects on tumor biology — some pro-survival pathways. Discuss with oncology before starting.
• Children under 18. No pediatric safety data.
• People who want a stimulant. NMN does not feel like caffeine. If you want acute energy, this is the wrong category.
• People who can't sustain daily dosing. Intermittent NMN is below threshold for the trial-replicated effects.
• People with severe MTHFR variants going straight to high doses. Add TMG, or stay at 500 mg.

Safety, interactions, and contraindications

• Anticoagulants (warfarin, DOACs). NMN itself has no documented anticoagulant effect, but Resveratrol (the typical stack pair) does have mild antiplatelet activity. Discuss the stack with your prescriber.
• Diabetes medications. NMN has shown insulin-sensitizing effects (Yoshino 2021). If you're on metformin, sulfonylureas, or insulin, monitor blood sugar — dose adjustment may be needed.
• Pre-surgery. Stop 7–14 days before any planned surgery (consistent with Resveratrol/general supplement-cessation guidance).
• Cancer therapy. NAD+ supplementation in active cancer treatment is not recommended without oncology input.
• MTHFR variants. Methylation considerations apply most at 1000 mg+. At 500 mg the load is small. If you have a known C677T or A1298C variant and want to be conservative, add TMG.
• Long-term use. Trial data is at most 12–24 months. Multi-year safety is undocumented but mechanistically clean — NMN converts to endogenous NAD+, which the body uses constantly anyway.
• Side effects. Mild GI discomfort or headache in <5% of users, typically resolves within 1–2 weeks. Discontinue if symptoms persist.

What's in it

Per capsule:

• 500 mg β-Nicotinamide Mononucleotide (≥99% HPLC purity).
• HPMC (vegetable cellulose) capsule shell.
• Rice flour as a flow agent (no magnesium stearate).
• No titanium dioxide. No artificial colors. No preservatives. No common allergens (gluten, soy, dairy, nuts, eggs, fish, shellfish).

Bottle: 60 capsules, UV-protective HDPE, oxygen barrier seal. Cool, dry, dark storage extends shelf life.

Sourcing, manufacturing, and quality control

• cGMP-certified manufacturing facility. ISO 9001 quality system.
• HPLC identity + purity per batch. ≥99% β-NMN. Certificate of analysis available for every lot.
• Heavy metals panel: lead, arsenic, cadmium, mercury — within USP-acceptable limits per batch.
• Microbial panel: total aerobic count, yeast/mold, E. coli, Salmonella — all within food-grade thresholds.
• Residual solvents: tested per USP <467>.
• Stability testing: β-purity verified at end of stated shelf life.

Lab reports are posted to our COA page. If you don't see your lot, email and we'll send the COA directly.

Frequently asked questions

Is NMN better than NR?

Different, not better. NMN has stronger evidence for metabolic and exercise-capacity endpoints (Yoshino 2021, Liao 2021, Yi 2022, Igarashi 2022). NR has stronger evidence for cardiovascular (Martens 2018) and brain (Brakedal 2022 NADPARK) endpoints. For a general user wanting an NAD+ precursor, NMN at 500 mg is the right starting point on cost, evidence base, and mechanism.

Can I take NMN with NR?

Yes. Different transporters (Slc12a8 for NMN, ENT1/2 for NR) — covering both gives broader tissue coverage. The methylation load is unchanged from either alone (both end as nicotinamide). At combined doses ≥1000 mg/day, add TMG.

How long until I notice anything?

Plasma NAD+ rises within hours. Subjective shifts in energy, training recovery, or sleep, if they're going to register, usually surface in week 2–4. Functional endpoints (endurance, gait speed) replicated in trials show by week 8–12. If 12 weeks of daily 500 mg gives you nothing subjective, step up to 1000 mg before concluding NMN doesn't work for you.

Can I take NMN at night?

Not recommended. NAD+ is a circadian wake signal — NMN raises NAD+ — evening dosing can disrupt sleep onset for sensitive users. Igarashi 2022 directly compared morning vs evening dosing in 65+ men and morning won on functional endpoints.

Do I need to cycle NMN?

No. NMN converts to endogenous NAD+ that the body already uses constantly. There's no receptor downregulation to worry about. Continuous dosing is the protocol used in every published positive trial.

Should I take it with food?

Yes. NMN absorption isn't food-dependent, but the sirtuin pathway pairs better with adequate dietary fat. Eggs, avocado, butter, nuts are good morning pairings.

What if I'm 30 — is NMN still useful?

NAD+ decline starts well before 30 — Massudi 2012 measured ~50% drop between 30 and 70, and most of that drop is in the second half of the curve, but it's already underway in your 30s. If you're a healthy 30yo with no metabolic issues, the case for NMN is more about preventive baseline maintenance than corrective; the upside per dollar is smaller than it is at 50. Decide based on price tolerance and whether you're optimizing for healthspan a long way out.

Why is NMN cheaper than NR?

NR-Cl is patented (the chloride salt form used in trials carries license cost). β-NMN supply has expanded faster, with multiple Asian manufacturers producing pharmaceutical-grade material. The result: NMN is typically 30–50% cheaper per gram of NAD+ precursor than NR. The trial-grade form is what matters; NMN at 500 mg gets you trial-replication at lower cost.

Can NMN replace coffee?

No. NMN raises NAD+ — the coenzyme for energy production — but it doesn't block adenosine receptors or cause acute alertness. Caffeine is a stimulant. NMN is upstream metabolic support. They do different things and most users keep both.

Will NMN show up on a drug test?

No. NMN is endogenous to mammalian metabolism — it's a normal cellular metabolite, not a foreign compound. Standard drug panels do not test for it, and athletic anti-doping (WADA) does not list it.

Can I take NMN while fasting?

Yes. NMN absorption isn't dependent on a meal. The sirtuin pathway actually upregulates during fasting, so NMN + fasting is mechanistically synergistic. Some users prefer fasted morning dosing; others find it sits better with food. Both are fine.

Does NMN raise blood pressure?

No. The NR cardiovascular trial (Martens 2018) actually showed a modest BP reduction in the elevated-BP subgroup. NMN's CV trial data is thinner but mechanistically similar — sirtuin activation favors vascular relaxation. No published NMN trial has reported BP increase as a side effect.

What's the maximum safe daily dose?

The highest tested dose in published human trials is 2000 mg/day (Pencina 2023, 14 days, healthy 55–80yo, no AEs). Most users will not need to exceed 1000 mg/day. There's no defined upper limit beyond what's been tested.

Does NMN interact with statins or blood-pressure medications?

No documented direct interactions at typical NMN doses. Sirtuin activation can modulate lipid metabolism (SIRT1 effects on cholesterol synthesis) but the magnitude is small relative to a statin. Coordinate with your prescriber if you're on cardiovascular medication.

How does NMN compare to NAD+ IV therapy?

IV NAD+ delivers a large bolus directly to plasma — onset is fast but pharmacokinetics are very different from oral precursor steady-state. The cost is also 10–50× higher per unit NAD+ delivered. For chronic, daily NAD+ support, oral NMN is the dominant mechanism on cost and convenience. IV has a niche for specific clinical contexts (addiction recovery protocols, acute neurological recovery) but is not a daily-protocol substitute for oral NMN.

Can I open the capsule?

Yes — NMN is bitter-tasting but not unpleasant. Pour the contents into water, smoothie, or yogurt. Some users prefer this for sublingual absorption (hold under the tongue 60–90s before swallowing). PK studies haven't shown a meaningful difference between sublingual and oral capsule absorption, but the option is there.

Is NMN vegan?

Yes. The β-NMN itself is synthesized; the capsule is HPMC (vegetable cellulose). No animal-derived ingredients in the product or the manufacturing process.

Will NMN help me sleep?

Indirectly. NMN doesn't sedate. But chronic NAD+ depletion correlates with sleep architecture disruption, and Kim 2022 reported sleep-quality improvement on 250 mg/day. Most users notice a subtle improvement in sleep depth over weeks 4–8 if they're going to notice anything.

Does NMN improve hair?

No published human trial directly tested this. Mechanistically, sirtuin activation supports hair-follicle stem-cell biology (animal data). Customer reports of better hair growth or thicker hair on long-term NMN are anecdotally common but not trial-replicated.

Why is daily consistency more important than dose?

The salvage pathway is a flow, not a tank. NAD+ pools depend on a constant supply rate — not on a periodic large bolus. Daily 500 mg vastly outperforms 3500 mg once a week, even though the totals match, because the cellular machinery responds to sustained substrate availability. One missed dose is fine. A week of skipped doses sets steady-state back.

Where this sits in the catalog architecture

Pure NMN 500 mg is the entry tier of the Foundational Health collection — the daily-baseline supplements that anchor everything else. The next tiers up are: NMN 1000 mg (higher dose, same molecule), NAD+ 5-in-1 (NMN + cofactors in one bottle), Liposomal NAD+ (direct NAD+ for maximum delivery), and the full Mitochondrial Renewal collection (CoQ10, PQQ, ALA, Urolithin A) for the structural-quality-control side of the same biology.

This product replaces nothing in the catalog; it slots underneath it. If you're new to the protocol, this is the first bottle.

Related collections

• Longevity Essentials — the 8 supplements that anchor the daily protocol.
• Foundational Health — daily-baseline products, including this one.
• Mitochondrial Renewal — energy + quality control.
• Sirtuin Activators — Resveratrol, Pterostilbene, the SIRT1 pair.

Read more on this topic

• NMN vs NAD+ — which should you take in 2026?
• NAD+ decline with age — what the evidence actually shows
• The classic longevity stack — NMN + Resveratrol + TMG
• Sirtuins explained — what SIRT1 and SIRT3 actually do
• Daily protocols by goal

Selected references

• Yoshino M et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 372:1224.
• Yi L et al. (2022). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience 45:29.
• Igarashi M et al. (2022). Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ levels and alters muscle function in healthy older men. npj Aging 8:5.
• Liao B et al. (2021). Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. J Int Soc Sports Nutr 18:54.
• Irie J et al. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal 67:153.
• Pencina KM et al. (2023). MIB-626, a microcrystalline unique polymorph of beta-nicotinamide mononucleotide, in adults with overweight or obesity. JCEM 108:1968.
• Fukamizu Y et al. (2022). Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. Sci Rep 12:14442.
• Kim M et al. (2022). Effect of 12-week intake of nicotinamide mononucleotide on sleep quality, fatigue, and physical performance in older Japanese adults. Nutrients 14:755.
• Grozio A et al. (2019). Slc12a8 is a nicotinamide mononucleotide transporter. Nature Metabolism 1:47.
• Luongo TS et al. (2020). SLC25A51 is a mammalian mitochondrial NAD+ transporter. Nature 588:174.
• Massudi H et al. (2012). Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLOS ONE 7:e42357.
• Camacho-Pereira J et al. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism 23:1127.
• Yoshino J et al. (2011). Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism 14:528.
• Mills KF et al. (2016). Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism 24:795.
• Imai S, Guarente L. (2014). NAD+ and sirtuins in aging and disease. Trends in Cell Biology 24:464.
• Bai P et al. (2011). PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metabolism 13:461.
• Escande C et al. (2013). Flavonoid apigenin is an inhibitor of the NAD+ ase CD38. Diabetes 62:1084.
• López-Otín C et al. (2013/2023). The hallmarks of aging. Cell 153:1194 / 186:243.
• Pacholec M et al. (2010). SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. JBC 285:8340.

References listed for context, not endorsement. The studies cited do not constitute a claim that this product treats, prevents, or cures any condition. Statements in this listing have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement, especially if pregnant, nursing, on medication, or under treatment for a medical condition.